-
16-05-2019, 10:37 AM
#2351
Originally Posted by sb9
Well done sb888, fully supportive of your views.
Thank you, glad there is someone else who sees it my way.
With all the positive views I have about the companys outlook, I still don't think theres much forgiveness for what they have done at Pokeno though, leaving shareholders ill-informed from the start, lack of due diligence in action they took and how messy that situation is.
In the sense of an analogy, its like a fruit basket, we have one rotten fruit in the basket of fruits, but that doesn't mean the whole basket of fruits is bad, but theres definitely a mess to clean up and for shareholders receiving the basket they are horrified by it.
Last edited by silverblizzard888; 16-05-2019 at 10:39 AM.
-
16-05-2019, 10:47 AM
#2352
Originally Posted by silverblizzard888
Thank you, glad there is someone else who sees it my way.
With all the positive views I have about the companys outlook, I still don't think theres much forgiveness for what they have done at Pokeno though, leaving shareholders ill-informed from the start, lack of due diligence in action they took and how messy that situation is.
In the sense of an analogy, its like a fruit basket, we have one rotten fruit in the basket of fruits, but that doesn't mean the whole basket of fruits is bad, but theres definitely a mess to clean up and for shareholders receiving the basket they are horrified by it.
In no way, I'm supportive of management's actions re Pokeno disaster. I did mention from their conf call following their FY results that current management need to pick up their act and they can probably take leaf out of A2's management team.
They (synlait management) need to be more professional, upfront and set their priorities aligned to shareholders interests. Don't think they are doing a great job of that currently. The current fiasco (if you want to call it that way) with Pokeno, am sure will be sorted out one way or other. In the meantime its going cost them more time and money.
Hope they learn lessons from this experience and no repetition of such events in future.
-
16-05-2019, 11:25 AM
#2353
Last edited by minimoke; 22-06-2019 at 10:57 AM.
Reason: Deleted by Minimoke in response to STMOD censorship of posts
-
16-05-2019, 02:05 PM
#2354
Member
More trouble for Synlait. And again, more subpar communication.
Munchkin fda approval for USA put on hold.
https://www.nzx.com/announcements/334649
Related to pokeno? Loss of production capability? Who knows.
-
16-05-2019, 02:39 PM
#2355
Last edited by minimoke; 22-06-2019 at 10:58 AM.
Reason: Deleted by Minimoke in response to STMOD censorship of posts
-
16-05-2019, 02:40 PM
#2356
Originally Posted by Chanchay
More trouble for Synlait. And again, more subpar communication.
Munchkin fda approval for USA put on hold.
https://www.nzx.com/announcements/334649
Related to pokeno? Loss of production capability? Who knows.
Quite considerate that they seem now to print the headlines of any bad news in bold pink. Makes them stand out of the crowd.
----
"Prediction is very difficult, especially about the future" (Niels Bohr)
-
16-05-2019, 03:34 PM
#2357
Last edited by minimoke; 22-06-2019 at 10:58 AM.
Reason: Deleted by Minimoke in response to STMOD censorship of posts
-
16-05-2019, 09:26 PM
#2358
Originally Posted by minimoke
Just a reminder from 2017
"He said the new timing will not have a material impact on Synlait's forecast volumes for the 2018 financial year. The company has previously said that significant manufactured volumes for the US market weren't expected until the 2018 financial year.
Synlait is expanding in the US, the world's second-largest infant formula market, to diversify its earnings away from China, the world's largest market. The company has worked for two years with Munchkin on the new 'grass-fed' formula which aims to meet demand for natural products in a market where much of the milk comes from intensive, factory-style dairy farms. The product is poised to become only the second imported infant formula brand with US FDA registration.
The company said today that the delay in the US launch has no impact on the strength of Munchkin's Grass Fed infant formula, which continues to steadily gain increased distribution in Australia and New Zealand."
Probably best to alert the market now and not do a PEB
Sorry minimoke, but what do you mean by a PEB?
-
16-05-2019, 09:31 PM
#2359
Last edited by minimoke; 22-06-2019 at 10:58 AM.
Reason: Deleted by Minimoke in response to STMOD censorship of posts
-
16-05-2019, 09:42 PM
#2360
Originally Posted by minimoke
Promising year after year that American certification is just around thecorner, sucking up shareholder funds in the meantime, paying extravagant executive wages and never ever getting close (PEB = Pacific Edge Biotech)
Ah yes, hope springs ever eternal in the hearts of both managers and investors. Only experience with lessons hard learned counteracts this (as you obviously have).
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks